Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in Renal Transplant Recipients
NCT02058589Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2014
- Primary completion
- May 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ), sponsored by GSK. Primary endpoints: Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity at 2 months, Number of Subjects With Solicited Local Symptoms at 7 days and 4 more. Started Mar 2014; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT02058589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058589.